SEEL Seelos Therapeutics Inc.

1.3
+0.28  (+27%)
Previous Close 1.02
Open 1.03
Price To Book 8.67
Market Cap 58,434,877
Shares 44,949,905
Volume 4,096,872
Short Ratio
Av. Daily Volume 1,312,094
Stock charts supplied by TradingView

NewsSee all news

  1. Seelos Therapeutics to Host Key Opinion Leader Call to Discuss the Unmet Medical Needs in Suicide and Depression

    NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  2. Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference

    NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  3. Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors

    NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  4. Seelos Therapeutics Receives Rare Pediatric Disease Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome

    NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  5. Seelos Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

    NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL issued for NDA resubmission - February 16, 2018. Noted April 16, 2017 two further Phase 3 trials required. Will need partner to finance trials.
Vitaros
Erectile dysfunction
Phase 2b/3 open-label trial to proceed soon. IND filing accepted August 22, 2019.
Trehalose (SLS-005)
Sanfilippo syndrome/MPS III
Phase 1 DDI initial data released January 10, 2020 - generally safe and well-tolerated.
SLS-002-101
Healthy volunteers
Phase 1 data due 2Q 2020.
SLS-002-102
Healthy volunteers

Latest News

  1. Seelos Therapeutics to Host Key Opinion Leader Call to Discuss the Unmet Medical Needs in Suicide and Depression

    NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  2. Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference

    NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  3. Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors

    NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  4. Seelos Therapeutics Receives Rare Pediatric Disease Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome

    NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  5. Seelos Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

    NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  6. Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)

    NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  7. Seelos Therapeutics Receives Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome

    NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  8. Seelos Therapeutics Provides Q1 2020 Business Update and Pipeline Developments

  9. Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)

    NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  10. Seelos Therapeutics Announces Closing of Public Offering of Common Stock

    NEW YORK, March 16, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  11. Seelos Therapeutics Announces Pricing of $4.5 Million Public Offering of Common Stock

    NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  12. Seelos Therapeutics Announces Proposed Public Offering of Common Stock

    NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  13. Seelos Therapeutics Announces European Medicines Agency Guidance to Design an Open-Label Pivotal Study for SLS-005 in Sanfilippo Syndrome

    NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  14. Seelos Therapeutics Receives Notice of Allowance for Composition of Matter Patent for SLS-007

    NEW YORK, March 06, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  15. ServiceSource Announces Four New Appointments to Board of Directors

    Company appoints Andrew M. Baker, Jane Okun Bomba, John A. Meyer, and Robin L. Smith Additions expand ServiceSource's Board with respected world-class leaders Planned retirement of three directors at the

  16. Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)

    NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  17. Seelos Therapeutics to Participate in Two Upcoming Investor Conferences in March

    Cowen 40th Annual Health Care Conference on March 2nd-4th in Boston, MARoth Capital 32nd Annual Conference on March 16th-17th in Laguna Niguel, CA NEW YORK, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics,

  18. Seelos Therapeutics Announces Closing of Public Offering of Common Stock

    NEW YORK, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  19. Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock

    NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  20. Seelos Therapeutics Announces Update to Parkinson's Disease Program SLS-007

    Delivery of SLS-007 to Utilize an Adeno-Associated Virus (AAV) VectorSLS-007 to Become Seelos' Second Gene Therapy Program Focused on Parkinson's  NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc.

  21. Seelos Therapeutics Announces Updates to SLS-005 (trehalose) Programs for Europe and U.S.

    NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  22. Seelos Therapeutics Announces Interim Data from Phase I Study of Intranasal Racemic Ketamine (SLS-002)

    NEW YORK, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  23. Seelos Therapeutics Schedules Type C Meeting with FDA to Discuss Intranasal Racemic Ketamine Program (SLS-002)

    NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  24. Sorrento Announces Dr. Robin Smith as New Member of the Board of Directors

    SAN DIEGO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )) announced today that Robin L. Smith, MD, MBA has been appointed to its Board of Directors. Dr. Smith is a

  25. Seelos Therapeutics to Participate in 33rd Annual National MPS Society Family Conference

    NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  26. Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)

    NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  27. Seelos Therapeutics Announces Dosing of Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002)

    NEW YORK, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  28. Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002)

    NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  29. Seelos Therapeutics Receives FDA Fast Track Designation for Intranasal Racemic Ketamine (SLS-002)

    NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare

  30. Seelos Therapeutics Reports Q3 2019 Pipeline Update

    NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company, today released its third quarter pipeline update. "Seelos continued to make significant

  31. Seelos Therapeutics to Participate in Upcoming Investor Conferences in December

    NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Evercore ISI 2nd Annual HealthCONx

  32. Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory Consultant

    NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company, today announced the addition of Scott Applebaum to its team as lead strategic regulatory

  33. Seelos Therapeutics to Participate in Upcoming Investor Conference in September

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Oppenheimer Fall Summit Focused on

  34. Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct Offering

    NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company, announced today that it has entered into a securities purchase agreement with certain

  35. Seelos Therapeutics Announces FDA Acceptance of IND Application for SLS-005 for Mucopolysaccharidosis Type III (Sanfilippo Syndrome)

    NEW YORK, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company, is pleased to announce the acceptance of the Investigation New Drug (IND) application for